RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azeliragon (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Early breast cancer
Focus Adverse reactions; Pharmacodynamics
Acronyms RAGE

24 Dec 2024 Planned End Date changed from 1 Nov 2024 to 1 Apr 2025.
24 Dec 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Mar 2025.
04 Jun 2024 Trial design assessing the role of TTP488 to decrease therapy related cardiac toxicity, and it will provide preliminary data about the safety, tolerability, and pharmacokinetics (PK) of common BC (neo)adjuvant chemotherapy agents in the presence of TTP488 were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com